Sector1:Pharmaceuticals ( Research Insight-1) Company 1: Cipla Ltd.

………………………………………………………………………………………………………………………………………………………………………………….

General Overview:

Cipla is leading pharmaceutical company from India with presence across the world. It was
established in 1935. The name of the company was changed to Cipla Limited in 1984 now
headquarter in Mumbai. The Revenue of this company is 19,160 crores till 2021. It is India's 42nd
largest publicly compony according to market value.

Cipla sells active pharmaceutical ingredients to other manufacturers as well as pharmaceutical and
personal care products including escitalopram oxalate, lamivudine and fluticasone propionate. Cipla
spent 517 crores on R&D activities. The primary focus areas for R&D were development of new
formulations and drug delivery systems.

Shareholding pattern of the company:

Holder's Name No of Shares % Share Holding

No. of Shares 806790214 100%

Promoters 114897947 14.24%

Foreign Institutions 195463457 24.23%

N Banks Mutual Funds 105568920 13.09%

Others 16369945 2.03%

General Public 128193400 15.89%

Financial Institutions 67217489 8.33%

Foreign Promoter 174907187 21.68%

GDR 4171869 0.52%

Management of the company:

Umang Vohra: ( Managing Director & Global Chief Executive Officer )

Umang Vohra has been Managing Director and Global Chief Executive Officer of Cipla since
September 2016. Umang joined Cipla in October 2015 as its Global Chief Financial Officer and from
January 2016 to August 2016 was Cipla’s Global Chief Operating Officer.

After pursuing degrees in engineering, marketing and finance, Umang was associated with
companies such as Eicher Motors and PepsiCo. Prior to joining Cipla, Umang was Head of the North
America business for Dr. Reddy’s Laboratories.

Umang is a firm believer in the power of agile business models, disruptive technologies, data-driven
analytics and a future-ready workforce with a view to shaping the healthcare ecosystem.

Kedar Upadhye: ( Global Chief Financial Officer )

Kedar Upadhye has been President and Global Chief Financial Officer of Cipla since July 2020,
heading its Global Finance and Information Technology functions. Prior to joining Cipla, Kedar was
Vice President, Finance, and Head of Investor Relations at Dr. Reddy’s Laboratories.

Kedar is a qualified Cost Accountant and Company Secretary, and an alumnus of the Indian Institute
of Management, Bangalore.

As a member of the Management Council of Cipla, Kedar is an integral part of decisions on identifying
levers of growth, strategic acquisitions and divestments, and cost optimisation projects.

Geena Malhotra: ( Global Chief Technology Officer )

Geena Malhotra has been President and Global Head – Manufacturing Operations. She is also leading
the Devices and Diagnostics Centre of Excellence at Cipla. Geena has played a key role in leading and
driving our Respiratory Innovation Engine. Under her leadership, the team has launched many
flagships products across global markets which has strengthened our leadership role in the
respiratory domain.

Geena Malhotra completed her Bachelors in Pharmacy in 1985 from Mumbai, and received her
Executive MBA degree from Washington University, St. Louis in 2017.

As a member of the Management Council of Cipla, Geena’s priorities are Operational Excellence,
Environment, Health & Safety Management, implementation of Good Engineering Practices & Process
Efficiency and reimagining operations in the digital world.

Dr. Ranjana Pathak: ( Global Head of Quality , Medical Affairs and Pharmacovigilance )
Dr. Ranjana Pathak is President - Global Quality, Medical Affairs and Pharmacovigilance at Cipla, has
been associated with the organisation for nearly six years. Ranjana has previously held leadership
roles in pharmaceutical companies such as Actavis, Endo Pharmaceuticals, Zenith Gold line and
Thames Pharmacol.

Ranjana has a Doctorate in Health Administration from the University of Phoenix, USA; an MBA from
Dowling College, New York; a Post-Graduate Diploma in Pharmaceutical & Chemical Analysis from
Sophia College, Mumbai; and a B.Sc. (Hons) in Chemistry from Mithibai College, Mumbai.
An industry veteran, Ranjana has over three decades of experience in pharma and brings to the table
extensive industry experience in dealing with regulatory bodies around the world.

Dr. Raju Mistry: ( Global Chief People Officer )

Dr. Raju Mistry has been President and Global Chief People Officer of Cipla since April 2019. Raju is
an accomplished and veteran HR leader with over 27 years of global experience across divers sectors
such as Chemicals, Pharma, FMCG, IT, Engineering and textiles.
At Cipla, Raju oversees Human Resources, and Administration and Facilities Management. As a
member of the Management Council of Cipla, Raju brings to the table her gravitas and expertise to
lead Cipla’s dynamic and ambitious people agenda with a keen focus on corporate culture, talent,
employer brand and leadership development.

SWOT Analysis:
SWOT Analysis of Cipla Limited is focus on strength , weaknesses ,opportunity and threats. In this
analysis strength and weakness are internal factors and Opportunities and Threats are the external
factor that influence the SWOT analysis of Cipla Limited.

Here is detailed representation of SWOT analysis:

Strength:
• Cipla offers different-different product that include human and animal healthcare goods.
Cipla offers over 2000 + items in 65 categories.
• Cipla has made significant investments in developing a strong portfolio. Brand portfolio helps
in growing in company.
• The products of Cipla are highly recognized by regulatory agencies in India and other
countries.
• Cipla has continued research in pharmaceutical sector and development of new drugs. For
this Cipla develop a robust infrastructure.
• Cipla always try to offers low-cost drugs/medicine to cancer. It also developed a "No Touch
Breast Scan".
• Successful training program is one of the Part of Cipla Limited also Cipla invested heavily in
employee training and development.

Weakness:
• Cipla's primary market is India. Although Cipla presence in all over 100+ countries.
• It has little clout in other developed markets and is heavily reliant on the Indian Market.
• High rivalry from domestic and global pharma business restricts Cipla's market share so this
is hurdle in expansion.
• No presence in the Japanese Market
• Second to P&G in market entry

Opportunity:
• Cipla provides a variety of medications for the treatment of HIV/AIDS in both children and
adults.
 • Cipla's medicine have the potential to treat an increasing number of people.
• Cipla is continuously expanding its business in India and also investment in research &
development.
• Cipla has acquired InvaGen Pharmaceuticals in the US among other things.
• Cipla could expand in developing countries where medical infrastructure is developing so
pharmaceutical is likely to grow.

Threat:
• Domestic and generic medicine are giving tough competition to Cipla Limited.
• If similar company uses new technology, then this is tough for Cipla in pharma sector. So
better is technical involvement is necessary.
• In medical sector, government regulations play a major role for any company. Pricing policy
changes have an impact on pharmaceutical firms.
• Other componies like Sun pharma, Cadila, Lupin etc. competing in the Indian generic sector,
this can impact on Cipla's growth.

Competitive Analysis:

S.N. Name Last Price Market Cap. Sales Net Profit Total Assets
(Rs. cr.) Turnover

1. Sun Pharma 820.90 196,961.41 12,803.21 2,139.70 31,525.70

2. Divis Labs 4,160.45 110,446.88 6,798.61 1,954.72 9,271.92

3. Cipla 934.90 75,429.04 13,900.58 2,468.28 19,927.56

4. Dr Reddys Labs 3,718.85 61,890.39 13,349.10 2,186.40 18,182.30

Conclusion:
On the basis of analysis, all the factor are important for company. Cipla wants their business
in all over the world, if company use new technology rather than old manufacturing method
then it will be plus point to compete other pharma company.

Technology plays a vital role in healthcare ecosystems. Cipla can increase their corporate
profile so this will help in to encounter domestic and global pharma business. Also,
Compony can increase business in developing country i.e., South Africa, Bangladesh etc.